This Medical Moments webinar series will review the latest guidelines on genetic testing/counseling and treatment recommendations, the emerging role of predictive biomarkers in ovarian cancer, and the latest evidence for the use of PARP inhibitors in treatment and maintenance settings, as well as in combination with other therapies. Additionally, there will be discussion regarding modifiable health equity issues that can be addressed in practice, as well as multidisciplinary strategies to the treatment and management of PARP inhibitor toxicities.

 

 

Click here for Digging Deep into the Genome: What Genetic Testing Can (and Can’t) Tell Us about Ovarian Cancer

 
 

Click here for Appraising Current Safety and Efficacy Data for PARP Inhibitors in Ovarian Cancer: Best Practices in Treatment and Adverse Event Management

 
 

Click here for Recognizing and Addressing the Elephant in the Room: Multidisciplinary Strategies to Mitigate Disparities in Ovarian Cancer Patients